Author

A. Hubstenberger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metagenomics· 1

Frequent Co-Authors

B. Mari· 1 shared B. Mograbi· 1 shared B. Romeo· 1 shared C. Lacoux· 1 shared C. Ventujol· 1 shared J. Fassy· 1 shared J. Roux· 1 shared K. Jacquet· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

B. Mari

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Processing body dynamics drive non-genetic MEK inhibitors tolerance by fine-tuning KRAS and NRAS translation

O. Vidal-Cruchez, V. J. Nicolini, T. Rete, R. Rezzonico, C. Lacoux, J. Fassy, K. Jacquet, M. A. Domdom, C. Ventujol, T. Juhel, B. Romeo, J. Roux, A. Hubstenberger, B. Mari, B. Mograbi, , P. Brest

The paper identifies a mechanism where MEK inhibitors induce tolerance by promoting KRAS and NRAS translation via PB dissolution, revealing a dynamic feedback loop in MAPK signaling.

bioRxiv · Dec 6, 2021 · PreprintCancer Biology